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ABSTRACT
Introduction: The Brazilian Uniﬁ ed Health Care System (SUS) offers treatment for patients with RA through federal 
funding (Ministry of Health) and state co-ﬁ nancing. The Clinical Protocol and Therapeutic Guidelines for the treatment of 
rheumatoid arthritis describe the therapeutic regimen for the disease, including the anticytokines adalimumab, etanercept 
or inﬂ iximab. Objectives: The aim of this study was to evaluate the proﬁ le of registered users of those anticytokines, 
biologics registered in the Information System of the Pharmaceutical Assistance Specialized Division, managed by the 
Paraná State Drug Center. Methods: A cross-sectional study regarding data from March 2010 was conducted. Based on 
dispensation data, information regarding the following variables were collected: age; gender; regional health care centers; 
International Classiﬁ cation of Diseases (ICD); and drug dispensed. In addition, the monthly cost with anticytokines for the 
SUS was calculated. Results: In the state of Paraná, 923 patients on anticytokines were identiﬁ ed, 40%, 44% and 16% of 
whom receiving adalimumab, etanercept and inﬂ iximab, respectively. This generated a monthly cost of R$3,403,195.59. 
Regarding the ICD, the distribution of patients was as follows: 55% had ICD M05.8; 27%, ICD M06.0; 9%, ICD M6.8; 
8%, ICD M5.0; and 1% had other ICDs related to the disease. The regional health care centers of the state of Paraná with 
the largest number of patients on anticytokines were in the following municipalities: Ponta Grossa; Cornélio Procópio; 
Londrina; Cianorte; Maringá; Irati; and Campo Mourão. Conclusion: This study assessed the distribution and proﬁ le of 
users of anticytokines for the rheumatoid arthritis treatment covered by the SUS in the state of Paraná, in March 2010.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inﬂ ammatory disease 
characterized by symmetrical peripheral polyarthritis, which 
leads to articular deformity and destruction due to bone and 
cartilage erosion.1–3 Its prevalence is approximately 1% of the 
world population.4 In Brazil, a multicenter study has reported 
an RA prevalence of 0.2%–1%.5
Patients with RA have a two-fold increased mortality risk. 
When RA involves other organs, its morbidity and severity are 
higher, and life expectancy can be reduced by 5–10 years.6 With 
disease progression, patients develop inability to perform their 
daily and professional activities. In addition, due to its chronic 
nature and the fact that RA affects individuals at a productive 
age, the disease has a high economic impact for the patient 
and the society.3,7
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Treatments for RA are aimed at preventing or controlling 
joint lesions, preventing functional loss, reducing pain, and 
maximizing the patients’ quality of life. The types of treat-
ment vary according to the disease stage, and complete disease 
remission is rarely achieved.1
For controlling both pain and the inﬂ ammatory process, non-
steroidal anti-inﬂ ammatory drugs (NSAIDs) and glucocorticoids 
are used. Once the diagnosis of RA is established, treatment with 
disease-modifying antirheumatic drugs (DMARDs) is recom-
mended, reducing RA signs and symptoms, and slowing the 
disease radiological progression. Examples of DMARDs are: 
methotrexate (MTX), leﬂ unomide (LFN), sulfasalazine (SFZ), 
and hydroxychloroquine (HCQ). Biological response modiﬁ ers 
are indicated for patients with persistently active disease despite 
treatment with NSAIDs and DMARDs. Some examples of 
biological response modiﬁ ers are tumor necrosis factor inhibi-
tors (anti-TNF) and anticytokines, such as adalimumab (ADA), 
etanercept (ETA), and inﬂ iximab (INF).1,8,9 According to the 
Methodological Guidelines for the Elaboration of Technical-
Scientiﬁ c Reports, the Brazilian Ministry of Health considers that 
those three anticytokines (ADA, ETA, and INF) have the same 
efﬁ cacy.10 Thus, physicians should choose among those drugs. 
Drugs for RA treatment are part of the list of the 
Pharmaceutical Assistance Specialized Division (CEAF) 
(Government Bulletin GM/MS #2,981/2009), former 
Exception Drug Dispensation Division (Government Bulletin 
GM/MS #2,577/2006). The Brazilian Uniﬁ ed Health Care 
System (SUS) offers treatment for patients with RA through 
federal funding (Ministry of Health) and state co-ﬁ nancing 
(Paraná State Secretariat of Health). The Paraná State 
Secretariat of Health, through the Paraná State Drug Center 
(CEMEPAR), is responsible for managing the Pharmaceutical 
Assistance in the state of Paraná.
CEMEPAR activities structured in the Pharmaceutical 
Assistance program comprise programming, acquisition 
forwarding, receiving, storing and distributing the CEAF list 
drugs to the Regional Health Care Centers of the Paraná State 
Secretariat of Health. The drugs are dispensed to patients resid-
ing in the state of Paraná by the Special Pharmacies of the 22 
Regional Health Care Centers. To be registered in the program, 
the patient should meet the criteria established in the Clinical 
Protocol and Therapeutic Guidelines for RA.10
The following factors are extremely important for planning 
the acquisition of drugs and managing the Pharmaceutical 
Assistance program: control of the number of patients registered, 
variations in the doses prescribed by physicians, drug replace-
ment and/or discontinuation, entrance of new patients, and exit 
of patients (discharge from the program, cure, abandonment 
of the program, or death). Based on that demand, CEMEPAR, 
along with the Paraná State Information Technology Company 
(CELEPAR), has developed, since 2004, the information system 
called SESAFARM. SESAFARM was the base for the creation 
of the system currently used at national level by the Ministry of 
Health, the CEAF Information System (SISMEDEX), implanted 
at all Special Pharmacies. SISMEDEX has the following func-
tionalities: (I) registration of the pharmacies and collaborators 
allowed to use the system; (II) data regarding drugs and ongoing 
Clinical Protocol and Therapeutic Guidelines; (III) registra-
tion of the user and the Exception Drug Request Form; (IV) 
registration of renovations and adequacies of the Exception 
Drug Request Form; (V) assessment and authorization of the 
process of drug request; (VI) registration of the dispensation 
of authorized drugs; (VII) registration and follow-up of the 
course of the process at the Regional Health Care Centers and/
or CEMEPAR; (VIII) maintenance of the registration of the 
prescribing physicians and Referral Centers belonging to the 
program; (IX) storage; (X) automatic generation of the High 
Complexity Procedure Authorization; (XI) generation of reports 
and general consultations.
This study aimed at establishing the proﬁ le of the users 
of anticytokines for the treatment of RA registered in CEAF, 
based on dispensation data obtained from SISMEDEX, and at 
assessing the following variables: International Classiﬁ cation 
of Diseases (ICD); gender; age; Regional Health Care Centers; 
and drugs dispensed. In addition, the monthly cost to SUS for 
acquiring those drugs was also assessed. This study was not 
aimed at discussing the access to the RA diagnosis, but exclu-
sively at assessing drug dispensation to patients diagnosed with 
RA and registered in the Pharmaceutical Assistance program.
MATERIAL AND METHODS
This is a cross-sectional study comprising data collection 
from users registered in SISMEDEX in the state of Paraná in 
March 2010. Data were collected through search for pathology, 
based on the Clinical Protocol and Therapeutic Guidelines for 
RA. The assessment considered data from patients with the 
following ICDs:
M05.0 – Felty’s syndrome;
M05.1 – Rheumatoid lung disease;
M05.2 – Rheumatoid vasculitis;
M05.3 – Rheumatoid arthritis with involvement of other organs 
or systems;
M05.8 – Other seropositive rheumatoid arthritis;
M06.0 – Seronegative rheumatoid arthritis;
M06.8 – Other speciﬁ ed rheumatoid arthritis.
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Data on ICD, gender, age, Regional Health Care Centers, 
and drug dispensed were collected for all patients, who were 
kept anonymous. The number and percentage of patients 
related to each of those variables were calculated. Mean age 
and its standard deviation were calculated, and the number of 
patients in each age group (every ﬁ ve years) was tabulated.
To calculate the resources used every month for the RA 
treatments in the state of Paraná, only the costs of the drugs 
at their usual recommended doses in the Clinical Protocol 
and Therapeutic Guidelines, obtained in the SUS database 
(DATASUS) tables, were considered.10
RESULTS
In the census carried out by the Brazilian Institute of Geography 
and Statistics (IBGE) in 2007, the Paraná state population was 
10,511,862 inhabitants, distributed in 399 municipalities.11 The 
number of users registered in SISMEDEX receiving treatment 
with anticytokines for RA in March 2010 was 923, of whom, 
258 (28%) were men and 665 (72%), women. Their age ranged 
from 2–91 years (mean age, 50 ± 13.8 years). Over half of the 
individuals (54.9%) were 40–60 years old. The patients’ age 
distribution is shown in Figure 1.
Regarding the ICD, the distribution was as follows: ICD 
M05.8, 55% of the individuals; ICD M06.0, 27%; ICD M06.8, 
9%; ICD M05.0, 8%; and other ICDs (M05.1, M05.2, M05.3, 
and M06.8), 1% of the individuals. The 923 patients registered 
in SISMEDEX were being treated as follows: 403 (44%) with 
ETA; 372 (40%) with ADA; and 148 (16%) with IFX.
The distribution of patients with RA receiving anticytokines 
in the state of Paraná is shown in Table 1. The  Regional Health 
Care Centers are presented in Figure 2.
Figure 1
Graphic representation of age as a function of the number of 
users of anticytokines registered in SISMEDEX.
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Table 1
Distribution of patients receiving anticytokines in the Regional 
Health Care Centers of the state of Paraná
Regional Health 
Care Centers n %
Total of 
inhabitants
Individuals/millions 
of inhabitants
01 – Paranaguá 20 2.2 287,633 70
02 – Metropolitana 319 34.6 3,385,145 94
03 – Ponta Grossa 60 6.5 579,827 103
04 – Irati 26 2.8 157,604 165
05 – Guarapuava 10 1.1 457,361 22
06 – União da Vitória 10 1.1 168,137 59
07 – Pato Branco 4 0.4 244,406 16
08 – Francisco Beltrão 11 1.2 313,370 35
09 – Foz do Iguaçu 31 3.4 450,893 69
10 – Cascavel 48 5.2 501,851 96
11 – Campo Mourão 59 6.4 311,945 189
12 – Umuarama 7 0.8 234,251 30
13 – Cianorte 16 1.7 130,687 122
14 – Paranavaí 18 2.0 254,256 71
15 – Maringá 108 11.7 716,273 151
16 – Apucarana 7 0.8 337,953 21
17 – Londrina 98 10.6 846,428 116
18 – Cornélio Procópio 26 2.8 243,178 107
19 – Jacarezinho 6 0.7 271,897 22
20 – Toledo 29 3.1 323,537 90
21 – Telêmaco Borba 7 0.8 166,466 42
22 – Ivaiporã 3 0.3 128,764 23
Total 923 100 10,511,862 88
Figure 2
Map of the Regional Health Care  Centers of the state of Paraná.
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Regarding the cost of the drugs, each ADA injection costs 
to SUS R$1,670.18. The total number of doses per year is 
27 (monthly mean of 2.25 doses). Thus, the monthly cost 
per patient is R$3,757.90. Multiplying by the number of pa-
tients (372), the total monthly cost reaches R$1,397,940.66. 
Regarding ETA, the unit cost of the 25-mg dose is R$523.32, 
while the 50-mg dose costs R$1,046.65. Every month, 257 
patients receive a mean of 8.7 doses/month of 25 mg (total of 
104 doses/year/ patient), and 146 patients receive a mean 
of 4.3 doses/month of 50 mg (total of 52 doses/year/patient), 
generating a total monthly cost of R$1,827,788.13. Regarding 
IFX, its dose costs R$1,713.00, and each patient receives, on 
average, eight doses per year. Considering the number of us-
ers (148), the total monthly cost reaches R$177,466.80. The 
total monthly cost with anticytokines in the state of Paraná in 
March 2010 was R$3,403,195.59, of which, ADA accounted 
for 41%, ETA, for 54%, and IFX, for 5%.
DISCUSSION
Despite the identiﬁ cation of more than 100 different types of 
cytokines and other factors involved in the pathogenesis of RA, 
TNF-α continues to play a signiﬁ cant role in joint erosive dis-
ease via osteoclast activation.12–15 TNF-α inhibitors have shown 
clear beneﬁ ts in randomized studies and controlled trials.16 
Rheumatoid arthritis can begin at any age, but its prevalence 
is from the fourth to the sixth decade.1,4 In the present study, 
more than half of the individuals assessed belong to that age 
group, being in accordance with data in the literature.
Rheumatoid arthritis affects twice more women than men, 
and its incidence increases with age. Gender differences, 
however, are not so marked as age advances.1,17,18 The users 
of anticytokines assessed in this study showed ﬁ gures similar 
to those reported.
The cause of RA is unknown, but several arthritogenic 
agents can stimulate the immune response in genetically 
susceptible individuals.18 In the state of Paraná, the Regional 
Health Care Centers of the following municipalities had the 
highest number of individuals undergoing treatment with 
anticytokines: Ponta Grossa; Cornélio Procópio; Londrina; 
Cianorte; Maringá; Irati; and Campo Mourão. It is worth not-
ing that the present study assessed the proﬁ le of patients really 
undergoing treatment for RA, and not of those with difﬁ culty 
in accessing either Regional Health Care Centers or physicians, 
or even difﬁ culty in being diagnosed with RA, who are, thus, 
left without proper treatment. In addition, there are individu-
als who buy their medication with their own resources, being, 
thus, not computed in SISMEDEX. 
The incidence of RA in Brazil is still underestimated. 
A study carried out in 200919 estimated that only half of 
the Brazilians with RA have their diagnosis established. 
The mean time between symptom onset and RA diagnosis 
was 1.8 year, which could have been due to difﬁ culty in 
accessing the public health care system. Other barriers for 
the treatment of RA in Brazil include low number of rheu-
matologists, population’s difﬁ culty in accessing the medi-
cations, and delay in scheduling the medical consultations, 
which can vary between four and ten months in different 
regions of the country.20
In the Clinical Protocol and Therapeutic Guidelines 
for RA,10 the three anticytokines are attributed the same 
efficacy. Some studies21–23 have compared the efficacy and 
safety of those drugs with those of placebo, and not directly 
between them. In the meta-analysis carried out in 2010, 
Wiens et al.24 reported that a difference in the efficacy 
and safety of those drugs might exist, and the prescribing 
physician should assess the risks and the benefits provided 
by each one. 
Currently, the prospective epidemiological study 
BiobadaBrasil is ongoing.25,26 In January 2011, that study in-
cluded 1,785 patients distributed in 32 centers. BiodabaBrasil 
aims at reporting data of effectiveness and safety of anticyto-
kines in the Brazilian population. The patients receive biologics 
or DMARDs (control group) for rheumatic diseases (69.7% of 
the patients have RA). So far, IFX has been reported as the most 
used drug (39% of the patients). In our study, a smaller number 
of IFX users was observed in the state of Paraná as compared 
with users of the other anticytokines. One factor accounting 
for that difference between the national data and those of the 
state of Paraná can be the choice of the anticytokines by the 
physicians. The anticytokine most frequently used in the state 
of Paraná in March 2010 was ADA.
The prescription and use of an anticytokine is an important 
decision, because it can generate a great impact on the patient’s 
quality of life by reducing RA symptoms, and also a signiﬁ cant 
cost elevation for the health care system.27 We assessed the 
cost of each medication for the SUS. However, to support the 
physician’s choice between anticytokines, that information 
is not enough, because pharmacoeconomic studies in Brazil 
are scarce. An economic study has been recently conducted 
by Venson et al.28 to assess the cost-effectiveness ratio of 
anticytokines for the RA treatment from the SUS perspective. 
Among the anticytokines, ADA and ETA showed the best 
cost-effectiveness ratio (R$511,633.00 and R$437,486.00, re-
spectively) as compared with IFX (R$657,593.00). Inﬂ iximab 
showed higher incremental cost-effectiveness ratio (ICER) per 
Proﬁ le of users of anticytokines offered by the health care system in the state of Paraná for the treatment of rheumatoid arthritis
207Rev Bras Reumatol 2012;52(2):203-213
outcome unit, which was R$965,927.00, while for ADA and 
ETA, those values were R$628,124.00 and R$509,974.00, 
respectively. However, despite the differences in the incre-
mental cost-effectiveness ratio between the anticytokines, it is 
worth noting that all three anticytokines should continue to be 
provided to the population, because each patient can respond 
differently to treatment.
In the context of RA treatment in the state of Paraná, this 
study established the proﬁ le of the users of anticytokines 
registered in CEMEPAR. In addition, the monthly cost with 
drugs for treating RA in that state could be assessed. Such 
values can be used for further economic evaluations, such as 
the cost-effectiveness ratio or even direct cost, from the SUS 
perspective, of the RA treatment in the state of Paraná. 
212 Rev Bras Reumatol 2012;52(2):203-213
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